Driven by increased demand in biologic-based drugs, biologic drug substance manufacturing continues to be an active area of investment by contract development and...

Biomanufacturing for both traditional biologics and new modalities, such as cell and gene therapies, continues to be an active area of investment for CDMOs/CMOS. Some of...

On November 1, 2020, Sean Diver took the reins as President of the Drug, Chemical & Associated Technologies Association (DCAT).

DCAT Value Chain Insights rounds up recent expansion activity for highly potent drug substances and drug products.